FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 7,709 other subscribers

Archives

Posts Tagged ‘clinical trials’

August 27, 2018

FORCE Co-Authors Paper on Engaging Patient Advocates in Research

by Lisa Schlager A year ago, I wrote a blog titled “Working with Industry to Increase Patient Engagement in Drug Development.”  In it, I shared that FORCE is a member of Bayer Pharmaceutical’s 5-member Patient Advocacy Advisory Council (PAAC), a novel partnership between this leading drug developer and the patient advocate community. From late 2016 … + read more

February 15, 2017

Guest Blog: Join FORCEs at our 2017 HBOC Conference!

by guest blogger, Jane E. Herman When I boarded the flight for my first trip to Orlando in June 2011, my goal was not to hug Mickey Mouse or visit Cinderella’s Castle. Rather, my destination was the sixth annual Joining FORCEs Conference. Not knowing anyone who would be in attendance, I was – not unexpectedly … + read more

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

July 28, 2016

Metastatic Hereditary Breast Cancer Treatment Research: BROCADE 3 Study

By Heather Han, MD and Sue Friedman Metastatic Hereditary Breast Cancer Research There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

May 10, 2016

Experience with Oncology Clinical Trial Participation and Impact on Future Trial Design and Conduct

Note: Last year, TESARO, a pharmaceutical company developing a new PARP inhibitor for treatment of ovarian cancer and metastatic breast cancer, asked FORCE to help recruit previous clinical trial participants to join focus groups across the U.S. TESARO wanted to understand the patient experience to build clinical trials that are more responsive to patient needs. We … + read more

March 30, 2016

Update on Pancreatic Cancer Genetics Research

By Talia Golan, MD and Sue Friedman, DVM BRCA and pancreatic cancer The link between breast and ovarian cancer and BRCA mutations has been known since the 1990s. However, the awareness that these mutations also increase pancreatic cancer risk is more recent. If all patients with pancreatic cancer were tested for a BRCA1 or BRCA2 … + read more

March 3, 2016

OlympiA: A Landmark Breast Cancer PARP Inhibitor Clinical Trial

by Sue Friedman Great progress has been made since the identification of the BRCA1 and BRCA2 genes and their link to causing breast, ovarian, pancreatic and other cancers. Over the last two decades, researchers have studied how BRCA mutations cause cancer in an effort to develop new treatments. In December 2014, Lynparza, (olaparib), a type … + read more

February 3, 2015

Spreading HBOC Advocacy to Japan

Last month I had the honor of giving two talks at a conference organized by the Japanese HBOC Consortium in Tokyo: one for patients and the other for health care providers. Most people in Japan have little input into their health care decisions and do not question their doctors’ recommendations. The conference organizers hoped that … + read more

June 29, 2014

FDA Approval of Promising Targeted Therapy Likely Stalled Until More Research Studies are Completed

Wednesday, June 25, 2014 was a pivotal day for our community. It began with promise and ended with disappointment. For the first time ever, a treatment targeted for BRCA-associated cancers was considered for approval by the FDA. Yesterday the FDA’s Oncologic Drug Advisory Committee (ODAC) held a hearing to consider FDA approval of the drug … + read more

March 24, 2014

Challenges to HBOC Research Enrollment: Competing Cancer Treatment Studies

Research is the key to better medical options. In prior blogs, I outlined some of the barriers to completing hereditary cancer research. This is the next blog in our series about addressing the barriers to hereditary cancer research. Hereditary cancers make up a small subset of a larger disease state. About 7% of all breast … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered